Sorry about the confusion. It may take a year for fertility to return in women who have had a Depo Prover injection, so it is not advisable for a woman seeking pregnancy within a year to use this (of course, ABC she never be used to avoid pregnancy

). It isn’t that Depo increases the risk of miscarriage or birth defects but the delay in return to fertility.
Ok. Here is some interesting stuff I am finding from the actual package insert. Should I start a new thread on this? Have I hijacked this thread?
*
6. Unexpected Pregnancies
To ensure that DEPO-PROVERA CI is not administered inadvertently to a pregnant woman, the first injection must be given **ONLY **during the first 5 days of a normal menstrual period; **ONLY **within the first 5-days postpartum if not breast-feeding, and if exclusively breast-feeding, **ONLY **at the sixth postpartum week (see DOSAGE AND ADMINISTRATION). Neonates from unexpected pregnancies that occur 1 to 2 months after injection of
DEPO-PROVERA CI may be at an increased risk of low birth weight, which, in turn, is associated with an increased risk of neonatal death. The attributable risk is low because
such pregnancies are uncommon.9,10 A significant increase in incidence of polysyndactyly and chromosomal anomalies
was observed among infants of users of DEPO-PROVERA CI, the former being most pronounced in women under 30 years of age. The unrelated nature of these defects, the lack of confirmation from other studies, the distant preconceptual exposure to DEPOPROVERA CI, and the chance effects due to multiple statistical comparisons, make a causal association unlikely.11 Neonates exposed to edroxyprogesterone acetate *in utero *and followed to adolescence, showed no evidence of any adverse effects on their health including their physical, intellectual, sexual, or social development. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in male and female fetuses. The risk of hypospadias (five to eight per 1,000 male births in the general population) may be approximately doubled with exposure to these drugs. There
are insufficient data to quantify the risk to exposed female fetuses, but because some of these drugs induce mild virilization of the external genitalia of the female fetus and
because of the increased association of hypospadias in the male fetus, it is prudent to avoid the use of these drugs during the first trimester of pregnancy. To ensure that DEPO-PROVERA CI is not administered inadvertently to a
pregnant woman, it is important that the first injection be given only during the first 5 days after the onset of a normal menstrual period within 5 days postpartum if not breastfeeding
and if breast-feeding, at the sixth week postpartum (see DOSAGE AND ADMINISTRATION).
This does not explain really what we were talking about but thought it was some interesting insight.
*